Evidence map›Paper›PMID 36806993›Full record

ArticleHuman cell2023

Impact of umbilical cord mesenchymal stromal/stem cell secretome and cord blood serum in prostate cancer progression.

André Sousa, Pedro Coelho, Fernanda Leite, Catarina Teixeira, Ana Catarina Rocha, Inês Santos, Pilar Baylina, Ruben Fernandes, Raquel Soares, Raquel Costa and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Human cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

André SousaUnit of Biochemistry, Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal.
Pedro CoelhoUnit of Biochemistry, Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal.
Fernanda Leitei3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Catarina Teixeirai3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Ana Catarina RochaUnit of Biochemistry, Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal.
Inês Santosi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Pilar Baylinai3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Ruben Fernandesi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.
Raquel SoaresUnit of Biochemistry, Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal.
Raquel Costa *Unit of Biochemistry, Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal.
Andreia Gomes *Unit of Biochemistry, Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal. andreiagomes@bebevida.com.ORCID http://orcid.org/0000-0002-3258-1773
Universidade do Porto · PTi3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto · PTCentro Hospitalar do Porto · PTFernando Pessoa University · PT

Funding

Fundação para a Ciência e a Tecnologia 2021.06521.BDFundação para a Ciência e a Tecnologia UID/BIM/0493/2020Instituto Politécnico do Porto IPP4COVID/BI/02/2020Porto Research, Technology & Innovation Center PORTIC/LabMi/BI/2021/03
6 · The paper itself

Abstract

Prostate cancer (PCa) is the second most common malignancy in men, and the fifth leading cause of death worldwide. Mesenchymal stromal/stem cells (MSC) have been identified in PCa, although contradictory effects in malignant transformation and tumor progression have been described. Since umbilical cord (UC) MSC and cord blood serum (CBS) are rich in numerous growth and anti-inflammatory factors, UC-MSC secretome and CBS are able to modulate tumor cell proliferation and survival as well as immunity and angiogenesis. In the present study, we address this relationship and investigate the influence of UC-MSC secretome and CBS on two human PCa cell lines (PC3 and LNCaP) and a normal epithelial prostate cell line (HPEpiC). Our results disclosed that upon exposure to UC-MSC-conditioned medium or CBS, both PC3 and LNCaP cells exhibited reduced viability, proliferation, and motility while non-malignant epithelial prostate cells were unaffected. These findings were corroborated by expression analysis of AKT/PI3K signaling pathway, p53 and interleukin genes. UC-MSC and CBS factors decreased the expression of growth-stimulating AKT and PI3K effectors and simultaneously up-regulated the expression of tumor-suppressor p53. Moreover, a more anti-inflammatory expression profile was found in both malignant PCa cell lines. Altogether, these results shed light into possible mechanisms by which UC-MSC and CBS reduce PCa progression, further reinforcing their potential use as novel therapeutic agents in PCa.

Indexed as

Prostatic NeoplasmsTumor Suppressor Protein p53HumansMalePhosphatidylinositol 3-KinasesProstateProto-Oncogene Proteins c-aktSecretomeSerumStem CellsUmbilical CordPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Suppressor Protein p53Acellular therapyCord blood serumMesenchymal stem/stromal cellsProstate cancerUmbilical cord

Identifiers

PMID36806993
PMCPMC10110723
OpenAlexW4321366474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.